MMP2 and interstitial lung disease: Furthermore, patients with RA-ILD+ undergoing conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) therapy showed decreased levels of MMP-2 compared to those not treated with csDMARDs (155844.92 pg/mL ± 27590.166 pg/mL vs. 186015.17 pg/mL ± 30834.722 pg/mL, p < 0.001).